Cargando…
Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay
Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419528/ https://www.ncbi.nlm.nih.gov/pubmed/30850576 http://dx.doi.org/10.12659/AJCR.914575 |
_version_ | 1783403962957824000 |
---|---|
author | Ramachandran, Preethi Farag, Fady Morcus, Rewais Gotleib, Vladimir |
author_facet | Ramachandran, Preethi Farag, Fady Morcus, Rewais Gotleib, Vladimir |
author_sort | Ramachandran, Preethi |
collection | PubMed |
description | Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced thrombocytopenia (aHIT) refers to a condition, in which antiplatelet factor-4 (PF4) antibodies activate platelets even in the absence of heparin (heparin independent platelet activation). This is a severe hypercoagulable state triggering massive thrombin storm needing additional therapies and aggressive anticoagulation apart from stopping heparin. Thrombocytopenia in these cases seems to be very severe and prolonged compared to classic HIT and poses additional clinical challenges in terms of anticoagulation management. Recently, direct oral anticoagulants (DOACs) seem to be an attractive option in the management of HIT as an alternative to vitamin K antagonists (VKA). CASE REPORT: We describe a case of a 55-year African American male who presented with pleuritic chest pain and was found to have worsening kidney disease. Clinical and electrocardiogram findings suggested uremic pericarditis, and dialysis was warranted. After 5 days of exposure to heparin flushes during dialysis, the patient developed thrombocytopenia, and subsequently HIT was diagnosed. Argatroban was started initially, however, his platelets count continued to drop, and he developed acute deep venous thrombosis of the right lower leg. IVIG (intravenous immunoglobulin) was started and his platelet count started to improve after several days. The patient was discharged on Eliquis and his platelet count returned to normal levels after 3 months. CONCLUSIONS: This case emphasizes the challenge managing HIT, a condition that has a high rate of complications. Several studies have reported platelet recovery with IV immunoglobulin when standard therapies fail. Recent evidence also supports the safety and efficacy of DOACs in offering a simplified way of managing these patients, especially in outpatient settings. |
format | Online Article Text |
id | pubmed-6419528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64195282019-04-17 Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay Ramachandran, Preethi Farag, Fady Morcus, Rewais Gotleib, Vladimir Am J Case Rep Articles Patient: Male, 55 Final Diagnosis: Auto-immune heparin thrombocytopenia -Treatment obstacles and challenging length of stay Symptoms: Thrombocytopenia • thrombosis Medication: — Clinical Procedure: IVIG Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Autoimmune heparin-induced thrombocytopenia (aHIT) refers to a condition, in which antiplatelet factor-4 (PF4) antibodies activate platelets even in the absence of heparin (heparin independent platelet activation). This is a severe hypercoagulable state triggering massive thrombin storm needing additional therapies and aggressive anticoagulation apart from stopping heparin. Thrombocytopenia in these cases seems to be very severe and prolonged compared to classic HIT and poses additional clinical challenges in terms of anticoagulation management. Recently, direct oral anticoagulants (DOACs) seem to be an attractive option in the management of HIT as an alternative to vitamin K antagonists (VKA). CASE REPORT: We describe a case of a 55-year African American male who presented with pleuritic chest pain and was found to have worsening kidney disease. Clinical and electrocardiogram findings suggested uremic pericarditis, and dialysis was warranted. After 5 days of exposure to heparin flushes during dialysis, the patient developed thrombocytopenia, and subsequently HIT was diagnosed. Argatroban was started initially, however, his platelets count continued to drop, and he developed acute deep venous thrombosis of the right lower leg. IVIG (intravenous immunoglobulin) was started and his platelet count started to improve after several days. The patient was discharged on Eliquis and his platelet count returned to normal levels after 3 months. CONCLUSIONS: This case emphasizes the challenge managing HIT, a condition that has a high rate of complications. Several studies have reported platelet recovery with IV immunoglobulin when standard therapies fail. Recent evidence also supports the safety and efficacy of DOACs in offering a simplified way of managing these patients, especially in outpatient settings. International Scientific Literature, Inc. 2019-03-09 /pmc/articles/PMC6419528/ /pubmed/30850576 http://dx.doi.org/10.12659/AJCR.914575 Text en © Am J Case Rep, 2019 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Ramachandran, Preethi Farag, Fady Morcus, Rewais Gotleib, Vladimir Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title | Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title_full | Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title_fullStr | Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title_full_unstemmed | Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title_short | Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay |
title_sort | autoimmune heparin-induced thrombocytopenia: treatment obstacles and challenging length of stay |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419528/ https://www.ncbi.nlm.nih.gov/pubmed/30850576 http://dx.doi.org/10.12659/AJCR.914575 |
work_keys_str_mv | AT ramachandranpreethi autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay AT faragfady autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay AT morcusrewais autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay AT gotleibvladimir autoimmuneheparininducedthrombocytopeniatreatmentobstaclesandchallenginglengthofstay |